CLOs on the Move

Pharmacy Access Solutions

www.pharmacyaccess.com

 
Pharmacy Access Solutions Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Hillsboro Medical Ctr

Hillsboro Medical Ctr is a Hillsboro, ND-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

AOS Research Inc

AOS Research Inc is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Talecris Plasma

Talecris Plasma is a Corpus Christi, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sarepta

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company`s programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases.

Repertoire

Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.